Kyrgyzstan Medical Device Registration: National Pathway vs EAEU Pathway

1. Key takeaways

Kyrgyzstan offers two market access routes for medical devices, and the choice between them can be compressed into three questions. First, how many union member states must the product enter? A product destined for Kyrgyzstan alone is better served by the national route, which is shorter and closer to the local regulator. A product that will also be placed in Russia, Kazakhstan and Belarus benefits from the Eurasian Economic Union route, where one registration covers several countries at once. Second, how frequently will the product change? Iterative software and active devices must budget for the repeated cost of migrating the dossier to union rules after 2028. Third, how much ready-made documentation is already in hand? Proof of circulation in the country of manufacture, the risk classification, and a favorable expert opinion should be inventoried before deciding where to file first.

2. Legal basis

1. Law of the Kyrgyz Republic on the Circulation of Medical Devices, Law No. 216 of December 29, 2023, Articles 14 and 15.
2. Cabinet Resolution No. 513, August 27, 2024, Annex 1 (national-route registration and expertise procedures).
3. Eurasian Economic Commission Council Decision No. 46, February 12, 2016 (union-route registration and expertise rules).
4. Eurasian Economic Commission Council Decision No. 106, November 10, 2017 (manufacturing inspections and quality management system requirements).
5. Protocol of December 29, 2025 amending the Agreement of December 23, 2014 (transition period).

3. Expert insights

Insight one: the real difference between the two routes is procedural ownership, not technical requirements.

As discussed in article 04, Article 2 of Cabinet Resolution No. 513 transfers all five technical rule sets to union decisions by reference. This means the technical threshold under the national route is highly congruent with the union route. The genuine difference lies in procedure: who accepts the application, who issues the conclusion, and whether that conclusion produces effect across several countries. Once this is understood, it becomes clear why the transition period matters so much for the national route: the technical requirements were always aligned, and it is the procedural difference that the transition period is designed to resolve.

Insight two: the value of the union route rises linearly with the number of countries covered and falls linearly with the frequency of change.

The union route carries a high fixed cost, because one full procedure includes technical testing, biological effects evaluation, clinical evaluation and a manufacturing inspection, with the file circulating between the reference state and the recognizing states. But each additional country adds very little marginal cost. Conversely, dossier changes under the union route must also circulate among member states, so frequently iterated products get dragged repeatedly into multilateral coordination. The product of these two variables is the true route cost.

Insight three: the time advantage of the national route comes from avoiding union-wide coordination.

Under the national route, the Department of Medicines and Medical Devices under the Ministry of Health is the single accepting authority. The standard procedure takes at most 50 calendar days from confirmation of fee payment, and the simplified channel for holders of certificates from the eight reference countries currently takes at most 30 calendar days (a draft amendment would compress this to 10 working days, still in draft status). The union route requires the reference state expert conclusion, approval by each recognizing state, and dispute mediation among member states, with cycles measured in months. For projects that need the certificate first and the business second, the national route has an obvious practical advantage.

Insight four: after the end of the transition period, a national-route file becomes a frozen dossier.

Registration certificates obtained under the national route are valid indefinitely (Article 15 of Law No. 216), but dossier changes can only be handled under national rules until December 31, 2028. From 2029, any change to the file must restart under union rules. This means a product certified in 2027 that needs a design change or a new model in 2029 will face a full union-route migration. For products with long lifecycles and many expected changes, this risk must be priced in.

4. Practical recommendations

First, run the three-question route test before starting any technical work. Use the three questions at the project kickoff meeting: number of target markets, expected change frequency, and existing certificate assets. The combination of answers normally points clearly to one route and avoids a costly mid-project switch.

Second, for multi-country programs, front-load the union route schedule. The union route is long and coordination-heavy. If new products are expected after 2028, start early rather than concentrating submissions near the end of the transition period, when testing laboratories and expert organizations will develop queues.

Third, for single-market projects that need a certificate urgently, the national route is a rational interim choice. But prepare a migration plan in parallel: record which technical evidence can be reused under the union route, which items must be redone, and the expected cost and duration of migration.

Fourth, for frequently changing product categories, evaluate the union route first. For software, active devices and consumables with fast formula iteration, if the product lifecycle will cross 2028, going directly through the union route is usually cheaper than the combination of the national route plus a later migration.

5. Verification checklist

• □ Define the target markets: Kyrgyzstan only, or a multi-country footprint including Russia, Kazakhstan, Belarus and Armenia;
• □ Assess whether the expected change frequency and product lifecycle extend beyond 2028;
• □ Complete an inventory of existing certificates (China NMPA, EU CE, US FDA, Japan PMDA and others);
• □ If choosing the union route: confirm the selection of the reference state and recognizing states (see article 17);
• □ If choosing the national route: prepare a union-route migration plan in parallel, listing reusable evidence and items to be redone;
• □ Confirm the filing deadline for the national route is 2027-12-31, and for re-registration and changes it is 2028-12-31.

Regulatory information verified as of October 29, 2026.

Our services cover: premarket pathway selection and feasibility assessment, registration dossier preparation and submission, authorized representative arrangements, local testing and clinical trial organization, manufacturing site inspection coordination, quality management system compliance support, post-market surveillance and vigilance system setup, import and distribution compliance, fee estimation and project budget management.

GRZAN provides regulatory registration support in Kyrgyzstan for medical device manufacturers, importers and authorized representatives, covering the full pathway from route selection to post-market obligations.

The GRZAN regulatory team consists of professionals with years of hands-on experience in Eurasian Economic Union registrations and maintains a stable local collaboration network in Bishkek, Almaty, Tashkent, Moscow and other cities, working in Chinese, Russian and English. We deliver actionable solutions for the issues foreign manufacturers most often encounter in the CIS region, including authorized representative arrangements, the notarization and legalization chain for powers of attorney, localization of technical documentation, and inspection readiness.

We hold to one principle: every regulatory conclusion we publish must rest on verifiable official sources. Figures and timelines that cannot be verified are labeled as a practical estimate, and experience-based values are never presented as legal requirements.

For project consultation on market access in Kyrgyzstan or the Eurasian Economic Union, contact us at info@grzanglobal.com.

GRZAN | Global Medical Device Regulatory Registration and Compliance Services